Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
37.36
-2.36 (-5.94%)
At close: Mar 31, 2025, 4:00 PM
36.00
-1.36 (-3.64%)
After-hours: Mar 31, 2025, 6:40 PM EDT

Company Description

Apogee Therapeutics, Inc., a clinical stage biotechnology company, advances novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.

The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD which is in phase 2; for the treatment of asthma and EoE which is in phase 1.

It also develops APG279 which is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Rα, for the treatment of Type 2 allergic diseases.

Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics, Inc.
Apogee Therapeutics logo
Country United States
Founded 2022
IPO Date Jul 14, 2023
Industry Biotechnology
Sector Healthcare
Employees 196
CEO Michael Henderson

Contact Details

Address:
221 Crescent Street, Building 17
Waltham, Massachusetts 02453
United States
Phone 650 394 5230
Website apogeetherapeutics.com

Stock Details

Ticker Symbol APGE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001974640
CUSIP Number 432705309
ISIN Number US4327053090
Employer ID 93-4958665
SIC Code 2836

Key Executives

Name Position
Dr. Michael Thomas Henderson M.D. Chief Executive Officer and Director
Jane Pritchett V. Henderson Chief Financial Officer
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer
Noel Kurdi Vice President of Investor Relations
Matthew Batters J.D. Chief Legal Officer and Corporate Secretary
Emily Cox Vice President and Head of People
Dr. Rebecca Dabora Ph.D. Chief Development Officer
Wendy Aspden-Curran Senior Vice President of Clinical Operations
Dr. Drew Badger Ph.D. Senior Vice President and Head of Regulatory Affairs and Toxicology
Monica Forbes Senior Vice President of Finance

Latest SEC Filings

Date Type Title
Mar 11, 2025 8-K Current Report
Mar 5, 2025 144 Filing
Mar 3, 2025 8-K Current Report
Mar 3, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 3, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 5, 2025 144 Filing
Feb 3, 2025 8-K Current Report
Jan 8, 2025 144 Filing
Dec 11, 2024 144 Filing